- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: CGRP.
Displaying page 1 of 1.
EudraCT Number: 2020-000661-16 | Sponsor Protocol Number: CGRP2020 | Start Date*: 2020-06-18 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet Glostrup | |||||||||||||||||||||||
Full Title: The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients | |||||||||||||||||||||||
Medical condition: Migraine | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-006219-28 | Sponsor Protocol Number: MRSI | Start Date*: 2022-02-24 |
Sponsor Name:Medical University Innsbruck | ||
Full Title: MR-Spectroscopy: Investigating neurochemical changes in brain metabolism in migraineurs before and after CGRPAntibody treatment – a randomized, controlled, open-label trial | ||
Medical condition: Episodic migraine | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006176-16 | Sponsor Protocol Number: I5Q-NS-O001 | Start Date*: 2022-09-26 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT) | |||||||||||||
Medical condition: High-frequency episodic migraine. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006136-29 | Sponsor Protocol Number: PDT-sBCC-MP-V1.0 | Start Date*: 2006-12-12 |
Sponsor Name:Peter Wolf MD, Department of Dermatology, Medical University of Graz | ||
Full Title: Mikroperfusions-Pilotstudie zur Korrelation von Schmerzreaktion und neurogener Entzündung bei photodynamischer Therapie superfizieller Basaliome (English: Microperfusion-pilotstudy to correlate pa... | ||
Medical condition: Superficial basal cell carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002224-32 | Sponsor Protocol Number: SYNCHRO | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d' Hebrón - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Sense, rhYhm & Networks: the study of how erenumab modulates CHROnic migraine | |||||||||||||
Medical condition: Chronic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001884-38 | Sponsor Protocol Number: I5Q-MC-CGAJ | Start Date*: 2015-12-07 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients with Migraine. | ||
Medical condition: Episodic or chronic migraine headache | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) BE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005063-28 | Sponsor Protocol Number: Emend2 | Start Date*: 2013-10-02 |
Sponsor Name:University of Gothenburg | ||
Full Title: Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant | ||
Medical condition: End stage renal disease under treatment with peritoneal dialysis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004622-28 | Sponsor Protocol Number: I5Q-MC-CGAT | Start Date*: 2021-02-22 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study | |||||||||||||
Medical condition: Chronic Migraine | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) DE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018309-12 | Sponsor Protocol Number: 02-2010 | Start Date*: 2010-02-26 |
Sponsor Name:Association REDAR, Hôpital Ambroise Paré, Service d'Anesthésie et de Réanimation | ||
Full Title: Etude bi-centrique, randomisée, en groupes parallèles et double aveugle contre placebo pour évaluer l’efficacité et la sécurité à long terme de la toxine botulique en deux administrations répétées ... | ||
Medical condition: Painful peripheral neuropathies related to mononeuropathies (eg, traumatic, postherpetic...) or to polyneuropathies (eg, diabetic, idiopathic...) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004351-23 | Sponsor Protocol Number: I5Q-MC-CGAS | Start Date*: 2021-02-22 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study | |||||||||||||
Medical condition: Episodic Migraine | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) DE (Completed) IT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003148-21 | Sponsor Protocol Number: BASICstudy | Start Date*: 2019-01-25 |
Sponsor Name:NTNU- Norwegian University of Science and Technology | ||
Full Title: BASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache | ||
Medical condition: Chronic cluster headache | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005246-15 | Sponsor Protocol Number: BHV3000-315 | Start Date*: 2022-08-23 | |||||||||||||||||||||
Sponsor Name:Biohaven Pharmaceuticals Holding Company Limited | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age | |||||||||||||||||||||||
Medical condition: Acute Migraine (with or without aura) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004994-25 | Sponsor Protocol Number: CSMS995A2101 | Start Date*: 2008-02-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorecta... | |||||||||||||
Medical condition: Irritable Bowel Syndrom | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001175-14 | Sponsor Protocol Number: BHV3000-406 | Start Date*: 2023-04-17 | |||||||||||
Sponsor Name:Biohaven Pharmaceuticals, Inc. | |||||||||||||
Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use | |||||||||||||
Medical condition: migraine attacks with or without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004337-32 | Sponsor Protocol Number: 3101-303-002 | Start Date*: 2020-02-12 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PR... | |||||||||||||
Medical condition: Chronic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) SE (Completed) PL (Completed) DE (Completed) DK (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
